Science Translational Medicine
20 May 2020 Vol 12, Issue 544
https://stm.sciencemag.org/

A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1
By Meta Roestenberg, Jona Walk, Saskia C. van der Boor, Marijke C. C. Langenberg, Marie-Astrid Hoogerwerf, Jacqueline J. Janse, Mikhael Manurung, X. Zen Yap, Amanda Fabra García, Jan Pieter R. Koopman, Pauline Meij, Els Wessels, Karina Teelen, Youri M. van Waardenburg, Marga van de Vegte-Bolmer, Geert Jan van Gemert, Leo G. Visser, André J. A. M. van der Ven, Quirijn de Mast, K. C. Natasha, Yonas Abebe, Tooba Murshedkar, Peter F. Billingsley, Tom L. Richie, B. Kim Lee Sim, Chris J. Janse, Stephen L. Hoffman, Shahid M. Khan, Robert W. Sauerwein

Science Translational Medicine20 May 2020 Full Access
The genetically attenuated malaria vaccine PfSPZ-GA1 is safe, immunogenic, and has suboptimal protective efficacy in people.